Navigation Links
YM BIOSCIENCES REPORTS ADDITIONAL RESULTS FROM NIMOTUZUMAB PHASE III STUDY IN CHILDREN WITH GLIOMA PRESENTED BY ONCOSCIENCE AG
Date:10/29/2009

aggressive chemotherapy and radiotherapy by Wolff et al (J Neuro Oncology Vol. 79. #3, September 2006).

The multi-centre, open-label, single-arm study was completed in 2007 and designed to evaluate the effectiveness of nimotuzumab combined with radiation in children with newly diagnosed DIPG, an inoperable form of brain cancer for which treatment options are severely limited. The study enrolled 42 patients aged 3 to 16 years (median 7 years) between April 2006 and August 2007, with 41 patients evaluable for response. The primary endpoint is reported to be "probability of a patient surviving progression-free six months post-diagnosis or median PFS over six months" and secondary endpoints included overall survival, response rate, toxicity and quality of life. The principal investigator is Professor Udo Bode at the University of Bonn, Germany.

"Nimotuzumab continues to demonstrate efficacy in trials throughout the world while avoiding the severe toxicities of the currently available EGFR-targeting drugs," said David Allan, Chairman and CEO of YM BioSciences. "These results underscore the value of a drug that can deliver benefit while maintaining quality of life. Adding to the body of safety and efficacy data for nimotuzumab, 48-month survival data from the randomized 4-arm "BEST" trial will be presented at ASTRO 2009 which will permit reviewers to observe the activity and efficacy of nimotuzumab in the absence of the severe toxicities of the class."

YM is currently conducting a Phase II study in children suffering from recurrent DIPG at ten of the principal oncology hospitals in the US as well as sites in Canada and Israel, with data expected in 2010. The drug is available on a compassionate use basis in the US for children with pediatric glioma and is designated an Orphan Drug for adult and pediatric glioma by the FDA as well as the EMEA for Europe.

ASTRO Presentation

An oral presentation will be delivered at th
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and BOSTON , Oct. ... ), a leading global specialty pharmaceutical company, and Rhythm, ... granted an exclusive option to acquire Rhythm,s wholly owned ... a peptide ghrelin agonist, for the treatment of diabetic ... Rhythm has completed a successful Phase 2 trial of ...
(Date:10/22/2014)... 22, 2014 Involution Studios , ... of a new infographic, Understanding Ebola . ... beautifully designed, easy to follow informative tool for anyone ... outbreak, symptoms and prevention. , "As the news has ... 2014 Ebola outbreak represents not only a healthcare crisis ...
(Date:10/22/2014)... Rock Hill, SC (PRWEB) October 22, 2014 ... the expansion of its cardiovascular pharmacogenetics menu, which ... improved patient outcomes. With PCLS’s evidence-based results, ... individual needs and optimize their therapy, while minimizing ... , In the U.S., according to the FDA ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... Diabetes Federation, approximately 400 million people worldwide are living ... 552 million people by 2030.  The global market for ... In 2012 approximately 330,000 people worldwide died from pancreatic ... of death due to cancer in the ...
Breaking Biology Technology:Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2
... 2011 Interleukin Genetics, Inc. (OTCQB: ILIU) announced ... Wedbush Securities Life Sciences Management Access Conference at the Le ... City. The presentation is scheduled for Wednesday, Aug. 17 at ... second floor.   Interleukin,s management team will be ...
... Mass., Aug. 10, 2011 Boston Scientific Corporation (NYSE: ... Institute™ (NLI), a clinical education program and online resource ... awareness of spinal cord stimulation (SCS) technology, procedures and ... meeting of the International Spine Intervention Society (ISIS) occurring ...
... DIEGO, Aug. 9, 2011 Verenium Corporation (Nasdaq: ... development and commercialization of high-performance enzymes, today reported a summary ... quarter and six months ended June 30, 2011. ... terms of product revenues and partnership negotiations in the first ...
Cached Biology Technology:Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference 2Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 2Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 3Boston Scientific Launches Neuromodulation Learning Institute To Enhance Clinical Education For Spinal Cord Stimulation 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 2Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 3Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 4Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 5Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 6Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 7Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 8Verenium Reports Financial Results for the Second Quarter and Six Months Ended June 30, 2011 9
(Date:10/17/2014)... from the University of Copenhagen have shown for the ... lungs of Cystic fibrosis patients, giving them the opportunity ... in chronic infections. , The study also discovered the ... (CF) patients was halted or slowed down by the ... all the oxygen and helped "suffocate" the bacteria, forcing ...
(Date:10/16/2014)... Oregon and Washington land managers have a new synthesis ... eastside moist mixed-conifer (MMC) forests in the two states. ... Forests in Eastern Oregon and Washington: A Synthesis of ... Management, a general technical report published by the U.S. ... response to a request from managers for a synthesis ...
(Date:10/16/2014)... 2014) – Post-menopausal women experienced improvements in vaginal ... or genital bleeding, after 12 weeks of daily ... soy germ-based nutritional supplement previously shown to help ... peer-reviewed pilot study reported in a poster at ... meeting. , "These data documented improved vaginal ...
Breaking Biology News(10 mins):Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2New report synthesizes best available science on management of moist mixed-conifer forests 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... the Department of Agriculture and Food Western Australia (DAFWA) ... Australia,s worst agricultural weeds. , "We are initiating a ... to control one and two-leaf Cape tulips (Moraea flaccida ... as a biological control agent," CSIRO Entomology,s Dr John ...
... on the miracle of life. The joining of egg and ... if the chromosome information from each parent has been translated ... is that when extra copies of chromosomes or fewer than ... birth defects can occur. Now, scientists at the University of ...
... may study grasses by profession, but Texas AgriLife Research forage agronomist Dr. Dariusz Malinowski ... And it is that ... Malinowski ... with his master,s degree in horticulture. , ...
Cached Biology News:Cape tulips -- pretty but pests in pastures 2UGA researchers propose model for disorders caused by improper transmission of chromosomes 2UGA researchers propose model for disorders caused by improper transmission of chromosomes 3Unique winter-hardy hibiscus has roots with AgriLife Research scientist in Vernon 2Unique winter-hardy hibiscus has roots with AgriLife Research scientist in Vernon 3
... preparations are prepared from customers high-copy ... to multi-gram scales. Each preparation is ... glycerol stocks are maintained to facilitate ... (Clonal selection includes screening colonies for ...
... channels for automated gigaseal patch clamping. ... voltage-gated ion channels, such as hERG and ... The four pipette heads afford more efficient ... drug discovery. The glass-coated tunnels of ...
... be able to handle larger sample volumes, automate ... as interface with telemetry systems. The AccuSampler ... dogs, pigs, and primates. The system may ... the computer can be located outside the animal ...
... The GST•Tag™ Antibody Plate is ... GST•Tag Monoclonal Antibody. This antibody (mouse ... S. japonicum glutathione-S-transferase (GST), ... virtually any GST•Tag fusion protein in ...
Biology Products: